Stock GENI GENERIC SWEDEN AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Generic Sweden AB

Equities

GENI

SE0001790791

Market Closed - Nasdaq Stockholm
Other stock markets
 10:41:47 2024-04-26 am EDT 		5-day change 1st Jan Change
52 SEK +1.96% Intraday chart for Generic Sweden AB +8.33% +0.39%
Feb. 15 Generic Sweden AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
2023 Generic Sweden AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 49% by 2025.
  • The group's high margin levels account for strong profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • The company benefits from high valuations in earnings multiples.
  • The company's enterprise value to sales, at 4.19 times its current sales, is high.
  • The company appears highly valued given the size of its balance sheet.
  • The valuation of the company is particularly high given the cash flows generated by its activity.

Ratings chart - Surperformance

Sector: Business Support Services

1st Jan change Capi. Investor Rating ESG Refinitiv
GENERIC SWEDEN AB Stock Generic Sweden AB
+0.39% 58.3M -
CINTAS CORPORATION Stock Cintas Corporation
+10.55% 67.6B
B+
JACOBS SOLUTIONS INC. Stock Jacobs Solutions Inc.
+11.64% 18.21B
B+
BUREAU VERITAS SA Stock Bureau Veritas SA
+21.03% 13.41B
A-
RB GLOBAL, INC. Stock RB Global, Inc.
+9.40% 13.37B
B-
INTERTEK GROUP PLC Stock Intertek Group plc
+16.53% 9.94B
B-
TELEPERFORMANCE SE Stock Teleperformance SE
-32.90% 5.74B
C
GENPACT LIMITED Stock Genpact Limited
-10.98% 5.57B
A-
MAXIMUS, INC. Stock Maximus, Inc.
-4.09% 4.91B
B-
EXLSERVICE HOLDINGS, INC. Stock ExlService Holdings, Inc.
-4.83% 4.87B
A-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
  1. Stock Market
  2. Equities
  3. GENI Stock
  4. Ratings Generic Sweden AB